Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients
Open Access
- 24 November 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0260656
Abstract
Therapeutic drug monitoring (TDM) is essential for voriconazole to ensure optimal drug exposure, mainly in critically ill patients for whom voriconazole demonstrated a large variability. The study aimed at describing factors associated with trough voriconazole concentrations in critically ill patients and evaluating the impact of voriconazole concentrations on adverse effects. A 2-year retrospective multicenter cohort study (NCT04502771) was conducted in six intensive care units. Adult patients who had at least one voriconazole TDM were included. Univariable and multivariable linear regression analyses were performed to identify predictors of voriconazole concentrations, and univariable logistic regression analysis, to study the relationship between voriconazole concentrations and adverse effects. During the 2-year study period, 70 patients were included. Optimal trough voriconazole concentrations were reported in 37 patients (52.8%), subtherapeutic in 20 (28.6%), and supratherapeutic in 13 (18.6%). Adverse effects were reported in six (8.6%) patients. SOFA score was identified as a factor associated with an increase in voriconazole concentration (p = 0.025), mainly in the group of patients who had SOFA score ≥ 10. Moreover, an increase in voriconazole concentration was shown to be a risk factor for occurrence of adverse effects (p = 0.011). In that respect, critically ill patients who received voriconazole treatment must benefit from a TDM, particularly if they have a SOFA score ≥ 10. Indeed, identifying patients who are overdosed will help to prevent voriconazole related adverse effects. This result is of utmost importance given the recognized COVID-19-associated pulmonary aspergillosis in ICU patients for whom voriconazole is among the recommended first-line treatment.Keywords
This publication has 18 references indexed in Scilit:
- Impact of voriconazole plasma concentrations on treatment response in critically ill patientsJournal of Clinical Pharmacy and Therapeutics, 2019
- Intensive care medicine research agenda on invasive fungal infection in critically ill patientsIntensive Care Medicine, 2017
- Liver — guardian, modifier and target of sepsisNature Reviews Gastroenterology & Hepatology, 2016
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2016
- Risk Factors for Voriconazole‐Associated Hepatotoxicity in Patients in the Intensive Care UnitPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Utility of voriconazole therapeutic drug monitoring: a meta-analysisJournal of Antimicrobial Chemotherapy, 2016
- Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2016
- The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled TrialClinical Infectious Diseases, 2012
- Therapeutic Drug Monitoring of Voriconazole and PosaconazolePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
- Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational studyInternational Journal of Antimicrobial Agents, 2010